Serial changes of cytokines in Crohn's disease treated with infliximab

Hepato-Gastroenterology

Volumn 58, Issue 110-111, 2011, Pages 1523-1526

  Mizutani, Tomomi ^a   Akasaka, Risaburo ^a   Tomita, Kazumitsu ^a   Chiba, Toshimi ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Crohn's disease; Cytokine levels; Infliximab

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COLON; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; ILEUM; INFLAMMATION; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

EID: 83355167058     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10170     Document Type: Article

References (31)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 2002; 359:1541-1549. (Pubitemid 34621118)
2. Lichtenstein GR, Feagan BG, Cohen RD, et al.: Serious Infections and Mortality in Association With Therapies for Crohn's disease: TREAT Registry. Clin Gastroentrol Hepatol 2006; 4:621-630.
3. Regueiro M, Schraut W, Baidoo L, et al.: Infliximab prevents Crohn's disease recurrence after ileal resection Gastroenterology 2009; 136:441-450.
4. Peluso I, Pallone F, Monteleone G: Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol 2006; 12:5606-5610. (Pubitemid 44594033)
5. Iwakura Y, Ishigame H: The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116:1218-1222.
6. Sandborn WJ, Feagan BG, Fedorak RM: A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135:1130-1141.
7. Feldmann M, Fionula M: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14:397-440. (Pubitemid 26130190)
8. Keating GM, Perry CM: Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 2002; 16:111-48. (Pubitemid 34533773)
9. Danese S, Sans M, Scaldaferri F, et al.: TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006; 176:2617-2624. (Pubitemid 43201714)
10. Ferkolj I, Ihan A, Markovic S, et al.: Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease. J Gastrointestin Liver Dis 2006; 15:231-235. (Pubitemid 44483090)
11. Lorenz HM, Antoni C, Valerius T, et al.: In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996; 156; 1646-1653.
12. Minderhoud IM, Samsom M, Oldenburg B: Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue? World J Gastroenterol 2007; 13:2089-93. (Pubitemid 46795847)
13. Gustot T, Lemmers A, Nicaise C, et al.: Profile of soluble cytokine receptors in Crohn's disease. Gut 2005; 54:488-495. (Pubitemid 40395500)
14. Nancey S, Hamzaoui N, Moussata D, et al.: Serum interleukin-6, soluble interleukin-6 receptor and Crohn's disease activity. Dig Dis Sci 2008; 53:242-247. (Pubitemid 350265676)
15. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
16. Shanahan F: Crohn's disease. Lancet 2002; 359:62-69.
17. MacDonald TT: The mucosal immune system. Parasite Immunol 2003; 25:235-246.
18. Atreya R, Mudter J, Finotto S, et al.: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat Med 2000; 6:583-588. (Pubitemid 30305911)
19. Fry TJ, Mackall CL: Interleukin-7: from bench to clinic. Blood 2002; 99:3892-3904. (Pubitemid 35332024)
20. Watanabe M, Ueno Y, Yaji T: Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest 1995; 95:2945-2953.
21. Daig R, Andus T: Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996; 38:216-222.
22. Mukaida N, Shiroo M, Matsushima K: Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol 1989; 143:1366-1371. (Pubitemid 19211374)
23. Izzo RS, Witkon K, Chien AI, et al.: Neutrophil activating peptide in colonic mucosa from patients with Crohn's disease. Scand J Gastroenterol 1993; 28:296-300.
24. Mitsuyama K, Toyunaga A, Sasaki E, et al.: IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol 1994; 96:432-436. (Pubitemid 24224862)
25. Nielsen OH, Rudiger N, Gaustadnes M, et al.: Intestinal interleukin 8 concentration and gene expression in inflammatory bowel disease. Scand J Gastroenterol 1997; 32:1028-1032.
26. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-146.
27. Kastelein RA, Hunter CA, Cua DJ: Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007; 25:221-242. (Pubitemid 46697908)
28. Caruso R, Sarra M, Stolfi C, et al.: Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 2009; 136:2270-2279.
29. Peluso I, Pallone F, Monteleone G: Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol 2006; 12:5606-5610. (Pubitemid 44594033)
30. Grimm MC, Doe WF: Chemokines in IBD mucosa: expression of RANTES, MIP-1α, MIPI-1βand interferon inducible protein 10 by macrophages, lymphocytes, endothelial cells and granulomas. Inflammatory Bowel Dis 1996; 2:88-96.
31. Banks C, Bateman A, Payne R, et al.: Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathology 2003; 199:28-35. (Pubitemid 36054726)